Literature DB >> 3167804

Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.

S R Petursson1.   

Abstract

A 20-year-old woman had a sporadic case of medullary thyroid carcinoma (MTC) metastatic to the lungs. After a transient response to streptozotocin and doxorubicin, new subcutaneous lesions appeared on the left chest wall and there was progression of pulmonary disease. Because MTC is one of the amine precursor uptake and decarboxylation (APUD) tumors, treatment was undertaken with agents active in these diseases. Dacarbazine and 5-fluorouracil, given daily for 5 days every 4 weeks, resulted in complete resolution of pulmonary and subcutaneous lesions and a sharp decrease in tumor marker levels that lasted 10 months. Recurrence of the pulmonary disease lead to her death 21 months after presentation. Thus, the chemo-responsiveness of MTC may be akin to that of other APUD carcinomas (APUDomas) and treatment of metastatic MTC and other APUDomas with the combination of dacarbazine and 5-fluorouracil appears to merit further study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167804     DOI: 10.1002/1097-0142(19881101)62:9<1899::aid-cncr2820620905>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.

Authors:  H Scherübl; F Raue; R Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  2012 European thyroid association guidelines for metastatic medullary thyroid cancer.

Authors:  M Schlumberger; L Bastholt; H Dralle; B Jarzab; F Pacini; J W A Smit
Journal:  Eur Thyroid J       Date:  2012-03-28

Review 4.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

Review 5.  Thyroid cancer: a review of treatment and follow-up.

Authors:  L Vini; C Harmer; V R McCready
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

Review 6.  Medullary thyroid cancer.

Authors:  E Kebebew; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2000-10

Review 7.  Medical management of metastatic medullary thyroid cancer.

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; James R Howe
Journal:  Cancer       Date:  2014-06-18       Impact factor: 6.860

8.  Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach.

Authors:  Adam S Fisch; Israa Laklouk; Masato Nakaguro; Vânia Nosé; Lori J Wirth; Daniel G Deschler; William C Faquin; Dora Dias-Santagata; Peter M Sadow
Journal:  Hum Pathol       Date:  2021-05-12       Impact factor: 3.526

9.  Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

Authors:  M Nocera; E Baudin; G Pellegriti; A F Cailleux; C Mechelany-Corone; M Schlumberger
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

10.  Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).

Authors:  M Schlumberger; N Abdelmoumene; M J Delisle; J E Couette
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.